Physician
Psychiatry
Dr. Daniel J. Safer, MD
|
|
Give Review
Daniel Safer practices Psychiatry. He went to medical school at University of Wisconsin School of Medicine and Public Health. Daniel Safer is a published doctor as well. He has 78 publications published. The latest was: Prevalence variations in psychotropic treatment of children. He accepts all Medicare patients.
Publications
- National Trends in Psychiatric Not Otherwise Specified (NOS) Diagnosis and Medication Use Among Adults in Outpatient Treatment.
- Recent Trends in Stimulant Usage.
- Antipsychotic prescribing for behavioral Disorders in US youth: physician specialty, insurance coverage, and complex regimens.
- Trends in Subthreshold Psychiatric Diagnoses for Youth in Community Treatment.
- Myosin VI Must Dimerize and Deploy Its Unusual Lever Arm in Order to Perform Its Cellular Roles.
- Atypical antipsychotic use among medicaid-insured children and adolescents: duration, safety, and monitoring implications.
- Number needed to harm: its limitations in psychotropic drug safety research.
- Prolactin serum concentrations during aripiprazole treatment in youth.
- Age-grouped differences in bipolar mania.
- Age-grouped differences in adverse drug events from psychotropic medication.
- Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.
- Psychotropic medication patterns among youth in foster care.
- Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.
- Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety Disorders?
- Anticonvulsant treatment for psychiatric and seizure indications among youths.
- Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents.
- Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.
- Multiple psychotropic medication use for youths: a two-state comparison.
- Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths.
- A comparison of risperidone-induced weight gain across the age span.
- Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity Disorder.
- Concomitant psychotropic medication for youths.
- Psychotropic practice patterns for youth: a 10-year perspective.
- Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
- Rising prevalence of antidepressants among US youths.
- Follow-up survey results of medication used to treat hyperactive school children.
- Depression of growth in hyperactive children on stimulant drugs.
- Drugs for problem school children.
- Effects of psychostimulants on aggression.
- Subgrouping conduct Disordered adolescents by early risk factors.
- Growth rebound after termination of stimulant drugs.
- Single daily dose methylphenidate in hyperactive children.
- Broader clinical considerations in child psychopharmacology practice.
- Stimulant drug treatment of hyperactive adolescents.
- Factors affecting outcome in a school mental health service.
- Effect of a media blitz and a threatened lawsuit on stimulant treatment.
- Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children.
- Drug comparison in hyperactive children.
- The Control of actin nucleotide exchange by thymosin beta 4 and profilin. A potential regulatory mechanism for actin polymerization in cells.
- A survey of medication treatment for hyperactive/inattentive students.
- "A familial factor in minimal brain dysfunction.
- Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective.
- Type and prevalence of medication used in the treatment of hyperactive children.
- Hyperactivity and inattentiveness. School assessment of stimulant treatment.
- Prevalence of medication treatment for hyperactive adolescents.
- Adolescent/adult differences in suicidal behavior and outcome.
- Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity Disorder.
- The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools.
- Adolescent stimulant use.
- An outpatient/inpatient comparison of child psychiatric diagnosis.
- Self-reported suicide attempts by adolescents.
- Are stimulants overprescribed for youths with ADHD?
- Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children.
- The impact of recent lawsuits on methylphenidate sales.
- Major treatment considerations for attention-deficit hyperactivity Disorder.
- Recent child pharmacoepidemiological findings.
- A comparison of studies from the United States and western Europe on psychiatric hospitalization referrals for youths exhibiting suicidal behavior.
- Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric Disorders.
- Pemoline hepatotoxicity and postmarketing surveillance.
- Stimulant treatment in Maryland public schools.
- Do antidepressants reduce suicide rates?
- Services and prevention: pharmacoepidemiology of antidepressant use.
- Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.
- Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s.
- Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland.
- Mental health services for youths in foster care and disabled youths.
- Trends in the prescribing of psychotropic medications to preschoolers.
- Methylphenidate patterns among Medicaid youths.
- Prevalence variations in psychotropic treatment of children.
- Increased methylphenidate usage for attention deficit Disorder in the 1990s.
- Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity Disorder.
- Antidepressant prevalence for youths: a multi-national comparison.
- Is there a connection between methylphenidate and cancer in youth?
- A three-country comparison of psychotropic medication prevalence in youth.
- Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.
- Irritable mood and the Diagnostic and Statistical Manual of Mental Disorders.
- Mood swing and Mood stabilizer: how specific are these terms?
Schools
University of Wisconsin Madison
DC General Hospital
Cleveland Psy Institute
Institute Juvenile Rsch
Johns Hopkins University
Procedures Preformed
- Psychiatric Evaluation
Conditions Treated
- Adjustment Disorder
- Borderline Personality Disorder
- Dysthymia and Cyclothymia (Mood Disorders)
- Impulse Control Disorders
- View All
Doctors Specialties
- Pediatric Psychiatry
- Psychiatry
Accepted Insurances
Education
-
Johns Hopkins University -
University of Wisconsin School of Medicine and Public Health
Drug Facts
| NPI NUMBER | 1134154222 | |
| NPPES Provider LastName | SAFER | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 212141315 | |
| NPPES Provider State | MD | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 417.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134154222 |
| Last Name Of The Provider | SAFER |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Gary A. Klein, MD |
|
|
Dr. Carlos A. Astrada, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Harris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Sarles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Riddle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denis G. Antoine II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn H. Watt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merrill I. Berman, MD |
|
|
Dr. Yura K. Williams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Joseph Mullen |